FFM
XENT

Fairmount Funds Management’s Intersect ENT, Inc XENT Stock Holding History

Fairmount Funds Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-80,238
Closed -$2M – 17
2019
Q4 		$2M Buy
+80,238
New +$1.63M 1.21% 13

Other funds holding XENT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fairmount Funds Management's XENT Position: Q1 2020 in Review

Fairmount Funds Management sold out of Intersect ENT, Inc (XENT) in Q1 2020, closing a stake of 80,238 shares — an estimated $2M sold.

Fairmount Funds Management first reported a position in XENT in Q4 2019 and held it in 1 quarter. The position peaked at $2M in Q4 2019. 121 funds tracked by Wall St. Rank hold XENT as of Q1 2020.

  • Fairmount Funds Management reported no remaining Intersect ENT, Inc position as of Q1 2020 after selling out during the quarter.
  • Fairmount Funds Management sold 80,238 Intersect ENT, Inc shares in Q1 2020, an estimated $2M.
  • Fairmount Funds Management first reported a position in Intersect ENT, Inc in Q4 2019 and held it in 1 quarter.
  • Fairmount Funds Management's Intersect ENT, Inc position peaked at $2M in Q4 2019.
  • 121 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2020.

Based on Fairmount Funds Management's 13F filing for Q1 2020, filed 8 May 2020.